Bio-Techne (formerly Techne Corp.), NASDAQ: TECH, is a global life sciences company providing innovative bioactive tools and resources for the research and clinical diagnostic communities.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Industrial Impact

BIO-TECHNE SETS A NEW STANDARD IN HIGHLY SENSITIVE RNA IMAGING WITH THE INTRODUCTION OF VIVID FLUORESCENT DYES FOR SPATIAL BIOLOGY

Bio-Techne | October 13, 2022

news image

Bio-Techne Corporation announced the introduction of 3 novel TSA Vivid Fluorophores for highly sensitive fluorescent detection of RNAs and proteins in cells and tissues. Optimized for use with proprietary RNAscope ISH technology, the TSA Vivid Fluorophores enable researchers to illuminate RNA biomarkers with industry leading sensitivity and clarity, accelerating cellular phenotyping and functional analysis at single-cell and subcellular resolution. Ideal for use with FFPE and fres...

Read More

BIO-TECHNE AND KANTARO BIOSCIENCES ANNOUNCE PARTNERSHIP TO DEVELOP AND SCALE PRODUCTION OF COVID-19 SEROLOGY TEST

Bio-Techne | May 19, 2020

news image

Bio-Techne Corporation (NASDAQ:TECH) and the Mount Sinai Health System in New York, through its commercial affiliate Kantaro Biosciences LLC (Kantaro), today announced a partnership to initiate scaled manufacturing and distribution of testing kits based on the Mount Sinai-developed COVID-19 serology test. Kantaro Biosciences is a joint venture between Mount Sinai Health System ("Mount Sinai") and Renalytix AI (LSE: RENX) formed exclusively to ensure that diagnostic tests for critical h...

Read More

BIO-TECHNE NETS FDA BREAKTHROUGH TICKET IN PROSTATE CANCER LIQUID BIOPSY

fiercebiotech | June 19, 2019

news image

Bio-Technes urine test, designed to track down the exosomes and genomic markers released from prostate cancer cells, has received a breakthrough device designation from the FDA for ruling out unnecessary tissue biopsies. The company describes its ExoDx Prostate IntelliScore test as the first liquid biopsy to receive breakthrough status for targeting exosomes, which are the small capsules released by cells carrying molecular cargo related to cell waste or communication and also bear RNA signature...

Read More

A FUTURE GENE THERAPY COULD BE DELIVERED IN TINY ‘NANOCONTAINERS’

Labiotech.eu | January 28, 2020

news image

A Swiss research group has developed tiny plastic particles that could carry gene therapies to the center of the cell with less risk of getting attacked by the immune system than conventional gene therapies. The majority of gene therapies in use today are delivered to the DNA of target cells using viral vectors. While efficient at their job, viral vectors can risk triggering the immune system to destroy them. This can lead to the therapy becoming ineffective....

Read More
news image

Industrial Impact

BIO-TECHNE SETS A NEW STANDARD IN HIGHLY SENSITIVE RNA IMAGING WITH THE INTRODUCTION OF VIVID FLUORESCENT DYES FOR SPATIAL BIOLOGY

Bio-Techne | October 13, 2022

Bio-Techne Corporation announced the introduction of 3 novel TSA Vivid Fluorophores for highly sensitive fluorescent detection of RNAs and proteins in cells and tissues. Optimized for use with proprietary RNAscope ISH technology, the TSA Vivid Fluorophores enable researchers to illuminate RNA biomarkers with industry leading sensitivity and clarity, accelerating cellular phenotyping and functional analysis at single-cell and subcellular resolution. Ideal for use with FFPE and fres...

Read More
news image

BIO-TECHNE AND KANTARO BIOSCIENCES ANNOUNCE PARTNERSHIP TO DEVELOP AND SCALE PRODUCTION OF COVID-19 SEROLOGY TEST

Bio-Techne | May 19, 2020

Bio-Techne Corporation (NASDAQ:TECH) and the Mount Sinai Health System in New York, through its commercial affiliate Kantaro Biosciences LLC (Kantaro), today announced a partnership to initiate scaled manufacturing and distribution of testing kits based on the Mount Sinai-developed COVID-19 serology test. Kantaro Biosciences is a joint venture between Mount Sinai Health System ("Mount Sinai") and Renalytix AI (LSE: RENX) formed exclusively to ensure that diagnostic tests for critical h...

Read More
news image

BIO-TECHNE NETS FDA BREAKTHROUGH TICKET IN PROSTATE CANCER LIQUID BIOPSY

fiercebiotech | June 19, 2019

Bio-Technes urine test, designed to track down the exosomes and genomic markers released from prostate cancer cells, has received a breakthrough device designation from the FDA for ruling out unnecessary tissue biopsies. The company describes its ExoDx Prostate IntelliScore test as the first liquid biopsy to receive breakthrough status for targeting exosomes, which are the small capsules released by cells carrying molecular cargo related to cell waste or communication and also bear RNA signature...

Read More
news image

A FUTURE GENE THERAPY COULD BE DELIVERED IN TINY ‘NANOCONTAINERS’

Labiotech.eu | January 28, 2020

A Swiss research group has developed tiny plastic particles that could carry gene therapies to the center of the cell with less risk of getting attacked by the immune system than conventional gene therapies. The majority of gene therapies in use today are delivered to the DNA of target cells using viral vectors. While efficient at their job, viral vectors can risk triggering the immune system to destroy them. This can lead to the therapy becoming ineffective....

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us